AbbVie (NYSE:ABBV) witnessed a selling pressure and the shares last traded with a loss of -0.76 points or -1.24% at $60.25. Investors jumped in to buy the shares on weakness. The net money flow till latest update was calculated at $29.1 million with an inflow of $110.81 million in upticks and an outflow of $81.7 million in downticks. Using the data, the up/down ratio is found to be 1.36. The share price has recorded -7.32% on a weekly basis.A block trade of $33.65 million in uptick and $8.59 million in downtick was also observed, resulting in an up/down ratio of 3.92. The net money flow of the block trade stood at a $25.07, signaling heavy buying.
Currently the company Insiders own 0.11% of AbbVie shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -16.87% . Institutional Investors own 66.78% of AbbVie shares. During last six month period, the net percent change held by insiders has seen a change of -14.58%. On the companys insider trading activities,The director officer (Chairman of the Board and CEO) of Abbvie Inc., Gonzalez Richard A sold 285,953 shares at $63.87 on June 2, 2016. The Insider selling transaction had a total value worth of $18,263,818. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
AbbVie (NYSE:ABBV) stock ended Monday session in the red zone in a volatile trading. The stock closed down 1.07 points or 1.75% at $59.93 with 11,673,621 shares getting traded. Post opening the session at $60.46, the shares hit an intraday low of $59.85 and an intraday high of $61.39 and the price was in this range throughout the day. The company has a market cap of $96,928 million and the number of outstanding shares have been calculated to be 1,617,358,600 shares. The 52-week high of AbbVie (NYSE:ABBV) is $71.6 and the 52-week low is $45.45.
Many analysts have stated their opinion on the company shares. Brokerage firm BMO Capital downgrades its rating on AbbVie (NYSE:ABBV). The shares have been rated Market Perform. Previously, the analysts had a Outperform rating on the shares. The rating by the firm was issued on June 10, 2016.
AbbVie Inc. (AbbVie) is a global, research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Companys products are focused on treating conditions, such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohns disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinsons disease; complications associated with chronic kidney disease and cystic fibrosis, and other health conditions, such as low testosterone. AbbVie also has a pipeline of new medicines, including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties, such as immunology, virology/liver disease, oncology, renal disease, neurological diseases and womens health. The Companys product portfolio includes HUMIRA, HCV products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products.